Kyverna Therapeutics, Inc.

Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company's pipeline centers on CD19-targeted CAR T-cell candidates designed to deplete B cells in patients with conditions including stiff person syndrome, myasthenia gravis, lupus nephritis, multiple sclerosis, and systemic sclerosis. Its lead program, KYV-101, is an autologous CAR T-cell therapy currently in clinical development. The company is also advancing KYV-102, which incorporates rapid whole blood manufacturing capabilities to simplify the manufacturing process, and KYV-201, an allogeneic CAR T-cell candidate intended to provide off-the-shelf therapy options.

Kyverna operates a collaboration agreement with Intellia Therapeutics to research and develop allogeneic CD19-directed CAR cell therapies, which extends the company's therapeutic platform. As a clinical-stage enterprise, the company does not currently generate product revenue and operates primarily on research and development activities.

The company is headquartered in Emeryville, California and operates with approximately 129 full-time employees. Kyverna was incorporated in Delaware in 2018, having previously operated under the name BAIT Therapeutics before its name change in October 2019. The company is listed on the Nasdaq exchange.